Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Accolade (NASDAQ: ACCD) has announced it will release its fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after market close. The company will host a conference call to discuss the results at 4:30 p.m. E.T. on the same day. Pre-registration is required for telephone access, and participants will receive dial-in details upon registration. The call will also be accessible via live audio webcast on the company's investor relations website. A replay will be available for one year on the same platform.
Accolade (NASDAQ: ACCD) has announced its participation in three upcoming investor conferences. The company will present at the Stephens Annual Investment Conference in Nashville on November 20 at 9:00 am CT, attend the CG MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21 (for one-on-one meetings only), and present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 5 at 10:00 am ET. Webcasts will be available at ir.accolade.com with replays accessible for 90 days, except for the CG MedTech event which will not be webcast.
Accolade, Inc. (Nasdaq: ACCD) has announced a partnership with Renalogic, a leader in managing chronic kidney disease (CKD) costs for self-insured employers. Renalogic will join Accolade's Trusted Partner Ecosystem, offering CKD risk management and dialysis cost containment solutions. This partnership aims to address the rising health costs for employers, particularly the high expenses associated with late-stage CKD and dialysis.
Renalogic's services include:
- ImpactIQ: Data algorithms to identify diagnosed and undiagnosed CKD members
- ImpactAdvocate: Support to delay end-stage renal disease and manage dialysis starts
- ImpactProtect: Advising on fair market rates for dialysis services
The partnership is expected to drive cost savings for customers while improving health outcomes for CKD members. Accolade and Renalogic will provide integrations to joint customers at no additional cost, including warm handoffs from Accolade Care Advocates to Renalogic's clinical team.
Accolade (NASDAQ: ACCD) announced financial results for fiscal Q2 2025 ended August 31, 2024. Revenue increased 10% to $106.4 million, while net loss improved 27% to $23.9 million. Non-GAAP Adjusted EBITDA loss narrowed 68% to $2.8 million, and Adjusted Gross Margin expanded to 47.3%.
CEO Rajeev Singh stated that Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positive cash flow. The company focuses on solving the Physician Gap through a physician-led advocacy approach. CFO Steve Barnes highlighted Accolade's execution in delivering profitable growth, with the net cash position improving by over $20 million compared to convertible debt in the past year.
Accolade, Inc. (NASDAQ: ACCD) has announced the release date for its fiscal second quarter 2025 financial results. The company will disclose the results on Tuesday, October 8, 2024, before market open. Following the release, Accolade will host a conference call at 8:00 a.m. E.T. to review the results.
Interested parties can participate in the conference call via telephone by pre-registering through a provided link. Upon registration, participants will receive dial-in information and a unique PIN. Alternatively, a live audio webcast of the call will be accessible online at the company's investor relations website. For those unable to attend live, a replay of the call will be available for one year via webcast on the same website.
Accolade (NASDAQ: ACCD) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Thursday, September 5 at 9:15 am ET in New York. Investors and interested parties can access a live webcast of the presentation through Accolade's investor relations website at ir.accolade.com. For those unable to attend or watch live, a replay of the presentation will be available on the same platform for 90 days following the event. This conference provides Accolade with an opportunity to showcase its healthcare technology solutions to a global audience of investors and industry professionals.
Celeste Health Solutions, a new healthcare company, is entering the market with an innovative approach to simplify healthcare access for employees and ease the burden for employers. The company integrates health navigation, personalized engagement, whole-person virtual care, point solutions, care management, and benefits support into a single, comprehensive product.
Key features of Celeste include:
- Smart care plans for each plan member
- An intuitive app for accessing all benefits
- Direct communication with Care Advocates
- The Innovations Hub, a curated portfolio of point solutions
- Consolidated contracting, billing, and reporting for employers
Celeste is partnering with Accolade (ACCD) to enhance personalization of health management services, combining virtual care options, expert medical opinions, clinical integration, and seamless navigation.
Accolade (NASDAQ: ACCD) has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston. The presentation is scheduled for Wednesday, August 14 at 12:00 pm ET. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website at ir.accolade.com. For those unable to attend or watch live, a replay of the presentation will be available on the same website for 90 days following the event.
This conference provides Accolade with an opportunity to showcase its growth strategies and recent developments to a wide audience of investors and industry professionals. The company's participation in such a prominent event suggests confidence in its business model and future prospects.
Accolade (NASDAQ: ACCD) announced its fiscal first-quarter 2025 results, highlighting significant improvements. The company reported a revenue increase of 18% year-over-year, reaching $110.5 million. Net loss improved by 28%, down to $27.6 million from $38.4 million in the same period last year. Adjusted EBITDA saw a substantial improvement of 73%, landing at negative $3.3 million compared to negative $12.6 million. Adjusted gross profit also rose by 30%, totaling $52.8 million, with an adjusted gross margin of 47.8%, up from 43.5%.
CEO Rajeev Singh emphasized Accolade's continued focus on healthcare accessibility and outcomes through their physician-led advocacy approach. CFO Steve Barnes highlighted the company's commitment to achieving profitable growth and positive Adjusted EBITDA within the year.
Accolade (NASDAQ: ACCD) announced the release date for its fiscal first quarter 2025 financial results. The report will be available on June 27, 2024, after the market closes. A conference call to review these results is scheduled for the same day at 4:30 p.m. ET. Interested parties must pre-register for the call, which will be accessible via telephone and a live audio webcast on Accolade's investor relations website. A replay of the call will be available for one year.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
